Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.
Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodríguez O, Guzman M, Sampath D, Nannini M, Xiao Y, Wagle MC, Wu JQ, Wongchenko M, Hampton G, Ramakrishnan V, Lackner MR, Saura C, Roda D, Cervantes A, Tabernero J, Patel P, Baselga J. Yan Y, et al. Clin Cancer Res. 2013 Dec 15;19(24):6976-86. doi: 10.1158/1078-0432.CCR-13-0978. Epub 2013 Oct 18. Clin Cancer Res. 2013. PMID: 24141624
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, Lorusso P, Brachmann R, Tong RK, Yan Y, Watts R, Bai S, Hegde PS. Xin Y, et al. Among authors: yan y. Clin Cancer Res. 2012 Nov 1;18(21):6040-8. doi: 10.1158/1078-0432.CCR-12-1652. Epub 2012 Sep 7. Clin Cancer Res. 2012. PMID: 22962439 Clinical Trial.
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Li C, Takahashi C, Zhang L, Huseni M, Stankovich B, Mashhedi H, Lee J, French D, Anderson JE, Kim D, Howell K, Brauer MJ, Kowanetz M, Yan Y, Humke E, Ebens A, Hampton G, Lackner MR, Hegde P, Jia S. Li C, et al. Among authors: yan y. J Transl Med. 2013 Mar 23;11:76. doi: 10.1186/1479-5876-11-76. J Transl Med. 2013. PMID: 23522020 Free PMC article.
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS. Sarker D, et al. Among authors: yan y. Clin Cancer Res. 2015 Jan 1;21(1):77-86. doi: 10.1158/1078-0432.CCR-14-0947. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370471 Free PMC article. Clinical Trial.
HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin.
Yu N, Kakunda M, Pham V, Lill JR, Du P, Wongchenko M, Yan Y, Firestein R, Huang X. Yu N, et al. Among authors: yan y. Mol Cell Biol. 2015 Apr;35(8):1390-400. doi: 10.1128/MCB.01307-14. Epub 2015 Feb 2. Mol Cell Biol. 2015. PMID: 25645927 Free PMC article.
19,342 results
You have reached the last available page of results. Please see the User Guide for more information.